Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
An innovative blood test that may spot more than 50 types of cancer will be piloted by the NHS in a world-leading programme, chief executive Sir Simon Stevens has announced.
The Galleri blood test, developed by GRAIL, can detect early-stage cancers through a simple blood test, and will be piloted with 165,000 patients in a world-first deal struck by NHS England.
If the NHS programme shows the test also works as expected for people without symptoms it will be rolled out to become routinely available.
The GRAIL pilot, which is due to start in mid-2021, will involve 165,000 people. That will include 140,000 participants aged 50 to 79 who have no symptoms but will have annual blood tests for three years.
People will be identified through NHS records and approached to take part. Anyone with a positive test will be referred for investigation in the NHS. Another 25,000 people with possible cancer symptoms will also be offered testing to speed up their diagnosis after being referred to hospital in the normal way.
Results of these studies would be expected by 2023, and if outcomes are positive, then they would be expanded to involve around one million participants across 2024 and 2025.
NHS Chief Executive Sir Simon Stevens said:
“While the good news is that cancer survival is now at a record high, over a thousand people every day are newly diagnosed with cancer. Early detection – particularly for hard-to-treat conditions like ovarian and pancreatic cancer – has the potential to save many lives. This promising blood test could therefore be a game-changer in cancer care, helping thousands more people to get successful treatment. This trial again confirms that the NHS is at the forefront of cutting edge treatments and technology.”
Health and Social Care Secretary, Matt Hancock said:
“We are building a world-leading diagnostics industry in the UK – not just for coronavirus but for other diseases too. This exciting and ground-breaking new blood test from GRAIL will give us another tool to give more people the very best chance of survival, demonstrating how the UK continues to lead the way in using the latest innovative treatments to help patients.
“Many of us know a loved one who has battled against cancer and have seen first-hand the impact of this deadly disease.”
Professor Peter Johnson, National Clinical Director for Cancer at NHS England and improvement said:
“The NHS has set itself an ambitious target, to find three-quarters of cancers at an early stage, when they have the highest chance of cure. Tests like this may help us get there far faster, and I am excited to see how this cutting-edge technology will work out, as we test it in clinics across the NHS.”
Sir Harpal Kumar, President of GRAIL Europe, said:
“The Long Term Plan for cancer is one I’ve been immensely supportive of since it was published, and I applaud the NHS and the government for setting out these ambitious goals and road map to diagnosing cancers earlier.
“Galleri, a simple blood test that’s capable of detecting more than 50 cancers, is a ground-breaking and potentially life-saving advance that could have a tremendous human and economic benefit. “Grail is thrilled to partner with the NHS and UK government to support the NHS Long Term Plan for earlier cancer diagnosis, and we are eager to bring our technology to patients in the UK as quickly as we can. I’m delighted we have the opportunity to work together to see if we can save many thousands more lives from cancer in the UK every year.”
Lord David Prior, Chair of NHS England said:
“Every year nearly 200,000 people in the UK die from cancer. Many of these people are diagnosed too late for treatment to be effective. This collaboration between the NHS and GRAIL offers the chance for a wide range of cancers to be diagnosed much earlier and could fundamentally change the outlook for people with cancer.”
This circular is being shared under the Open Government Copyright licence.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.